Good News for Amarin: AstraZeneca Abandoning its Fish Oil Pill | NASDAQ. AstraZeneca(NYSE: AZN) announced on Monday that it was discontinuing the phase 3 Strength clinical study evaluating Epanova in reducing cardiovascular risk. The British drugmaker said that the decision was made after the study's independent data monitoring committee determined that there was a "low likelihood" that Epanova would help patients with mixed dyslipidemia (MDL) who are at risk of cardiovascular disease. Epanova won U.S. Food and Drug Administration (FDA) approval in 2014 for treating adult patients with severe hypertriglyceridemia, a condition where patients have triglyceride levels of at least 500 mg/dL. AstraZeneca picked up the drug in 2013 with its acquisition of Omthera Pharmaceuticals. The drug's sales were never high enough to even warrant a mention in any of AstraZeneca's annual regulatory filings. AstraZeneca undertook the large-scale Strength study in hopes that it could position Epanova as a drug that could reduce cardiovascular risk.
1 other references
Latest Stories From Referenced Companies
Feb 28, 2020
Feb 27, 2020